|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SH3BGRL3 |
Gene summary for SH3BGRL3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SH3BGRL3 | Gene ID | 83442 |
| Gene name | SH3 domain binding glutamate rich protein like 3 | |
| Gene Alias | HEL-S-297 | |
| Cytomap | 1p36.11 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q9H299 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 83442 | SH3BGRL3 | GSM4909281 | Human | Breast | IDC | 7.83e-06 | 3.25e-01 | 0.21 |
| 83442 | SH3BGRL3 | GSM4909285 | Human | Breast | IDC | 2.14e-03 | -1.74e-01 | 0.21 |
| 83442 | SH3BGRL3 | GSM4909286 | Human | Breast | IDC | 1.65e-14 | -4.10e-01 | 0.1081 |
| 83442 | SH3BGRL3 | GSM4909290 | Human | Breast | IDC | 1.45e-08 | -5.65e-01 | 0.2096 |
| 83442 | SH3BGRL3 | GSM4909293 | Human | Breast | IDC | 7.43e-04 | 1.29e-02 | 0.1581 |
| 83442 | SH3BGRL3 | GSM4909296 | Human | Breast | IDC | 1.97e-07 | 8.26e-02 | 0.1524 |
| 83442 | SH3BGRL3 | GSM4909297 | Human | Breast | IDC | 7.22e-18 | -3.93e-01 | 0.1517 |
| 83442 | SH3BGRL3 | GSM4909298 | Human | Breast | IDC | 2.51e-06 | -3.25e-01 | 0.1551 |
| 83442 | SH3BGRL3 | GSM4909311 | Human | Breast | IDC | 8.34e-38 | -6.68e-01 | 0.1534 |
| 83442 | SH3BGRL3 | GSM4909312 | Human | Breast | IDC | 3.12e-20 | -6.17e-01 | 0.1552 |
| 83442 | SH3BGRL3 | GSM4909315 | Human | Breast | IDC | 3.44e-06 | 2.82e-01 | 0.21 |
| 83442 | SH3BGRL3 | GSM4909319 | Human | Breast | IDC | 1.14e-43 | -3.67e-01 | 0.1563 |
| 83442 | SH3BGRL3 | GSM4909321 | Human | Breast | IDC | 7.28e-09 | -3.30e-01 | 0.1559 |
| 83442 | SH3BGRL3 | ctrl6 | Human | Breast | Precancer | 7.74e-04 | 4.21e-01 | -0.0061 |
| 83442 | SH3BGRL3 | brca1 | Human | Breast | Precancer | 1.51e-51 | 7.62e-01 | -0.0338 |
| 83442 | SH3BGRL3 | brca2 | Human | Breast | Precancer | 4.57e-16 | 3.94e-01 | -0.024 |
| 83442 | SH3BGRL3 | brca3 | Human | Breast | Precancer | 5.25e-10 | 3.91e-01 | -0.0263 |
| 83442 | SH3BGRL3 | brca10 | Human | Breast | Precancer | 4.35e-23 | 6.15e-01 | -0.0029 |
| 83442 | SH3BGRL3 | NCCBC14 | Human | Breast | DCIS | 3.32e-05 | 1.52e-02 | 0.2021 |
| 83442 | SH3BGRL3 | NCCBC3 | Human | Breast | DCIS | 2.82e-02 | 7.38e-02 | 0.1198 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SH3BGRL3 | SNV | Missense_Mutation | rs373102479 | c.94C>T | p.Arg32Cys | p.R32C | Q9H299 | protein_coding | tolerated(0.14) | benign(0.009) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
| SH3BGRL3 | SNV | Missense_Mutation | rs373102479 | c.94N>T | p.Arg32Cys | p.R32C | Q9H299 | protein_coding | tolerated(0.14) | benign(0.009) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SH3BGRL3 | SNV | Missense_Mutation | novel | c.163G>T | p.Gly55Cys | p.G55C | Q9H299 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-EO-A22T-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SH3BGRL3 | SNV | Missense_Mutation | novel | c.220N>C | p.Tyr74His | p.Y74H | Q9H299 | protein_coding | tolerated(0.06) | probably_damaging(0.992) | TCGA-EO-A3AY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
| SH3BGRL3 | SNV | Missense_Mutation | novel | c.147N>C | p.Glu49Asp | p.E49D | Q9H299 | protein_coding | tolerated(0.06) | possibly_damaging(0.811) | TCGA-55-7913-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
| SH3BGRL3 | SNV | Missense_Mutation | rs200815881 | c.95N>A | p.Arg32His | p.R32H | Q9H299 | protein_coding | tolerated(0.24) | benign(0.001) | TCGA-99-8025-01 | Lung | lung adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | gemzar | SD |
| SH3BGRL3 | SNV | Missense_Mutation | novel | c.131N>G | p.Asn44Ser | p.N44S | Q9H299 | protein_coding | tolerated(0.65) | benign(0.03) | TCGA-CR-7370-01 | Oral cavity | head & neck squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |